113 related articles for article (PubMed ID: 25421662)
1. Epigenetics of prostate cancer.
McKee TC; Tricoli JV
Methods Mol Biol; 2015; 1238():217-34. PubMed ID: 25421662
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
3. [Epigenetics of prostate cancer].
Yi XM; Zhou WQ
Zhonghua Nan Ke Xue; 2010 Jul; 16(7):635-41. PubMed ID: 20873600
[TBL] [Abstract][Full Text] [Related]
4. Studying the epigenome using next generation sequencing.
Ku CS; Naidoo N; Wu M; Soong R
J Med Genet; 2011 Nov; 48(11):721-30. PubMed ID: 21825079
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic changes in prostate cancer: implication for diagnosis and treatment.
Li LC; Carroll PR; Dahiya R
J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340
[TBL] [Abstract][Full Text] [Related]
7. Cancer type-specific epigenetic changes: gastric cancer.
Calcagno DQ; de Arruda Cardoso Smith M; Burbano RR
Methods Mol Biol; 2015; 1238():79-101. PubMed ID: 25421656
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic modifications in prostate cancer.
Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
[TBL] [Abstract][Full Text] [Related]
9. Next generation sequencing in epigenetics: insights and challenges.
Meaburn E; Schulz R
Semin Cell Dev Biol; 2012 Apr; 23(2):192-9. PubMed ID: 22027613
[TBL] [Abstract][Full Text] [Related]
10. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
11. Next-generation technologies and data analytical approaches for epigenomics.
Mensaert K; Denil S; Trooskens G; Van Criekinge W; Thas O; De Meyer T
Environ Mol Mutagen; 2014 Apr; 55(3):155-70. PubMed ID: 24327356
[TBL] [Abstract][Full Text] [Related]
12. Introduction into the analysis of high-throughput-sequencing based epigenome data.
Huss M
Brief Bioinform; 2010 Sep; 11(5):512-23. PubMed ID: 20457755
[TBL] [Abstract][Full Text] [Related]
13. The value of new high-throughput technologies for diagnosis and prognosis in solid tumors.
Pinto R; De Summa S; Petriella D; Tudoran O; Danza K; Tommasi S
Cancer Biomark; 2014; 14(2-3):103-17. PubMed ID: 24878811
[TBL] [Abstract][Full Text] [Related]
14. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
15. The DNA methylation landscape of advanced prostate cancer.
Zhao SG; Chen WS; Li H; Foye A; Zhang M; Sjöström M; Aggarwal R; Playdle D; Liao A; Alumkal JJ; Das R; Chou J; Hua JT; Barnard TJ; Bailey AM; Chow ED; Perry MD; Dang HX; Yang R; Moussavi-Baygi R; Zhang L; Alshalalfa M; Laura Chang S; Houlahan KE; Shiah YJ; Beer TM; Thomas G; Chi KN; Gleave M; Zoubeidi A; Reiter RE; Rettig MB; Witte O; Yvonne Kim M; Fong L; Spratt DE; Morgan TM; Bose R; Huang FW; Li H; Chesner L; Shenoy T; Goodarzi H; Asangani IA; Sandhu S; Lang JM; Mahajan NP; Lara PN; Evans CP; Febbo P; Batzoglou S; Knudsen KE; He HH; Huang J; Zwart W; Costello JF; Luo J; Tomlins SA; Wyatt AW; Dehm SM; Ashworth A; Gilbert LA; Boutros PC; Farh K; Chinnaiyan AM; Maher CA; Small EJ; Quigley DA; Feng FY
Nat Genet; 2020 Aug; 52(8):778-789. PubMed ID: 32661416
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer epigenome.
Chinaranagari S; Sharma P; Bowen NJ; Chaudhary J
Methods Mol Biol; 2015; 1238():125-40. PubMed ID: 25421658
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
Stirzaker C; Song JZ; Davidson B; Clark SJ
Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
[TBL] [Abstract][Full Text] [Related]
18. Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers.
Yamashita S; Takahashi S; McDonell N; Watanabe N; Niwa T; Hosoya K; Tsujino Y; Shirai T; Ushijima T
Cancer Res; 2008 Apr; 68(7):2112-21. PubMed ID: 18381416
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic biomarkers: A new perspective in laboratory diagnostics.
García-Giménez JL; Sanchis-Gomar F; Lippi G; Mena S; Ivars D; Gomez-Cabrera MC; Viña J; Pallardó FV
Clin Chim Acta; 2012 Oct; 413(19-20):1576-82. PubMed ID: 22664147
[TBL] [Abstract][Full Text] [Related]
20. Compendium of aberrant DNA methylation and histone modifications in cancer.
Hattori N; Ushijima T
Biochem Biophys Res Commun; 2014 Dec; 455(1-2):3-9. PubMed ID: 25194808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
